New Cell Sorting Method Tracks Cancer Mutations at Single-Cell Level
STAR-FACS technique enables researchers to isolate and study rare cancer cells with specific mutations, revealing how genetic changes drive tumor behavior.
Summary
Researchers developed STAR-FACS, a new method that sorts cells based on specific DNA mutations using fluorescent labeling. The technique works by amplifying mutation-specific DNA sequences inside intact cells, then using flow cytometry to separate mutant from normal cells. This allows scientists to study how rare cancer-driving mutations affect gene expression and chromatin structure at the single-cell level, which was previously difficult with existing methods.
Detailed Summary
Cancer researchers at The Herbert Wertheim UF Scripps Institute have developed a groundbreaking cell sorting technique called STAR-FACS that can isolate rare cancer cells based on specific DNA mutations. This innovation addresses a critical gap in cancer research: understanding how single nucleotide variants (SNVs) drive tumor behavior at the cellular level.
The STAR-FACS method works by performing PCR amplification directly inside paraformaldehyde-fixed cells to generate mutation-specific DNA sequences. These sequences are then labeled with fluorescent probes, allowing researchers to use standard flow cytometry equipment to sort cells carrying particular mutations from those without them. The sorted cells can then be analyzed using RNA sequencing or chromatin profiling techniques.
The researchers validated their approach using glioblastoma cell lines with different TERT promoter mutations - genetic changes found in 80-90% of glioblastomas that affect telomerase activity. They successfully demonstrated that cells with different TERT promoter variants (C228T vs C250T mutations) could be separated and showed distinct transcriptional programs when analyzed. The method achieved high specificity, with sorted populations showing 85-95% enrichment for the target mutation.
This technique has significant implications for cancer research and potentially therapeutic development. Many clinically important mutations that drive therapy resistance exist in only small subpopulations of tumor cells, making them difficult to study with conventional bulk sequencing methods. STAR-FACS enables researchers to isolate these rare mutant cells and understand their unique biological properties, including how they interact with neighboring normal cells.
The method is cost-effective compared to single-cell DNA/RNA co-sequencing approaches and uses standard laboratory equipment, making it accessible to most research labs. However, the current protocol requires prior knowledge of specific mutations to target and works best with well-characterized hotspot mutations rather than novel variants.
Key Findings
- STAR-FACS achieved 85-95% enrichment of target mutant cells from mixed populations using standard flow cytometry equipment
- Glioblastoma cells with C228T vs C250T TERT promoter mutations showed distinct transcriptional programs when isolated and analyzed
- The method successfully worked on both cultured cell lines and primary dissociated tumor tissue samples
- In-cell PCR amplification generated sufficient fluorescent signal for cell sorting without compromising cell viability for downstream analysis
- Sorted cells retained RNA and chromatin integrity suitable for bulk RNA-seq and CUT&Tag chromatin profiling
- The technique detected mutations present in as few as 5-10% of cells in mixed populations
- TERT promoter mutant cells showed upregulation of telomerase-related pathways compared to wild-type cells
Methodology
The study used glioblastoma cell lines and primary tumor samples with known TERT promoter mutations (C228T and C250T). Cells were fixed with paraformaldehyde, permeabilized, and subjected to in-cell PCR using mutation-specific primers and fluorescent probes. Flow cytometry was used to sort labeled cells, which were then analyzed by RNA sequencing and CUT&Tag chromatin profiling. Multiple cell lines and primary samples were tested to validate the approach across different genetic backgrounds.
Study Limitations
The method requires prior knowledge of specific mutations to target and works best with well-characterized hotspot mutations. The current protocol is optimized for TERT promoter mutations and may need adaptation for other genomic regions. The study was conducted primarily on glioblastoma samples, so broader validation across cancer types is needed. Authors noted potential for false positives due to PCR artifacts and emphasized need for careful primer design.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.